Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice

Robert S B Clark, Vincent A. Vagni, Paula D. Nathaniel, Larry W. Jenkins, C. Edward Dixon, Csaba Szabo

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme best known for its role in DNA repair and as a mediator of NAD+ depletion and energy failure-induced cell death. We tested the effect of the potent and selective ideno-isoquinolone PARP-1 inhibitor INO-1001 after controlled cortical impact (CCI) in mice. Anesthetized adult male mice were subjected to moderate CCI (velocity 6 m/sec, depth 1.2 mm) or sham-injury. Immediately after CCI or sham-injury mice received either INO-1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 μl over 5 min) in a randomized fashion. At 2 h, contused brain tissue was dissected and NAD+ levels were measured. Separate mice underwent neuropathological outcome tests that included spatial memory acquisition (Morris water maze days 14-20), and assessment of contusion volume and hippocampal cell death at day 21. Local treatment with INO-1001 preserved brain NAD+ levels 2 h after CCI (vehicle = 67 ± 7.6, INO-1001 = 95.8 ± 4.4 % uninjured hemisphere; n = 6/group, p = 0.03). In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI (n = 11/group, p ≤ 0.05). Histological damage did not differ between vehicle and INO-1001-treated mice after CCI. Treatment with INO-1001 prevented NAD+ depletion and improved outcome, although modestly, identifying PARP-mediated energy failure as a contributor to the pathological sequelae of TBI. Further study testing the effects of PARP inhibitors is warranted, specifically in models of brain injury where energy failure is seen.

Original languageEnglish (US)
Pages (from-to)1399-1405
Number of pages7
JournalJournal of Neurotrauma
Volume24
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

NAD
Water
Contusions
Cell Death
Wounds and Injuries
Brain
Poly(ADP-ribose) Polymerase Inhibitors
Traumatic Brain Injury
INO 1001
DNA Repair
Brain Injuries
Therapeutics
Injections
Enzymes

Keywords

  • Controlled cortical impact
  • Head injury
  • Ideno-isoquinolone
  • Nicotinamide adenine dinucleotide
  • Poly(ADP-ribose) synthetase

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. / Clark, Robert S B; Vagni, Vincent A.; Nathaniel, Paula D.; Jenkins, Larry W.; Dixon, C. Edward; Szabo, Csaba.

In: Journal of Neurotrauma, Vol. 24, No. 8, 08.2007, p. 1399-1405.

Research output: Contribution to journalArticle

Clark, Robert S B ; Vagni, Vincent A. ; Nathaniel, Paula D. ; Jenkins, Larry W. ; Dixon, C. Edward ; Szabo, Csaba. / Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. In: Journal of Neurotrauma. 2007 ; Vol. 24, No. 8. pp. 1399-1405.
@article{f716c4457c7b49a1b4f35346c36057d4,
title = "Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice",
abstract = "Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme best known for its role in DNA repair and as a mediator of NAD+ depletion and energy failure-induced cell death. We tested the effect of the potent and selective ideno-isoquinolone PARP-1 inhibitor INO-1001 after controlled cortical impact (CCI) in mice. Anesthetized adult male mice were subjected to moderate CCI (velocity 6 m/sec, depth 1.2 mm) or sham-injury. Immediately after CCI or sham-injury mice received either INO-1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 μl over 5 min) in a randomized fashion. At 2 h, contused brain tissue was dissected and NAD+ levels were measured. Separate mice underwent neuropathological outcome tests that included spatial memory acquisition (Morris water maze days 14-20), and assessment of contusion volume and hippocampal cell death at day 21. Local treatment with INO-1001 preserved brain NAD+ levels 2 h after CCI (vehicle = 67 ± 7.6, INO-1001 = 95.8 ± 4.4 {\%} uninjured hemisphere; n = 6/group, p = 0.03). In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI (n = 11/group, p ≤ 0.05). Histological damage did not differ between vehicle and INO-1001-treated mice after CCI. Treatment with INO-1001 prevented NAD+ depletion and improved outcome, although modestly, identifying PARP-mediated energy failure as a contributor to the pathological sequelae of TBI. Further study testing the effects of PARP inhibitors is warranted, specifically in models of brain injury where energy failure is seen.",
keywords = "Controlled cortical impact, Head injury, Ideno-isoquinolone, Nicotinamide adenine dinucleotide, Poly(ADP-ribose) synthetase",
author = "Clark, {Robert S B} and Vagni, {Vincent A.} and Nathaniel, {Paula D.} and Jenkins, {Larry W.} and Dixon, {C. Edward} and Csaba Szabo",
year = "2007",
month = "8",
doi = "10.1089/neu.2007.0305",
language = "English (US)",
volume = "24",
pages = "1399--1405",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice

AU - Clark, Robert S B

AU - Vagni, Vincent A.

AU - Nathaniel, Paula D.

AU - Jenkins, Larry W.

AU - Dixon, C. Edward

AU - Szabo, Csaba

PY - 2007/8

Y1 - 2007/8

N2 - Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme best known for its role in DNA repair and as a mediator of NAD+ depletion and energy failure-induced cell death. We tested the effect of the potent and selective ideno-isoquinolone PARP-1 inhibitor INO-1001 after controlled cortical impact (CCI) in mice. Anesthetized adult male mice were subjected to moderate CCI (velocity 6 m/sec, depth 1.2 mm) or sham-injury. Immediately after CCI or sham-injury mice received either INO-1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 μl over 5 min) in a randomized fashion. At 2 h, contused brain tissue was dissected and NAD+ levels were measured. Separate mice underwent neuropathological outcome tests that included spatial memory acquisition (Morris water maze days 14-20), and assessment of contusion volume and hippocampal cell death at day 21. Local treatment with INO-1001 preserved brain NAD+ levels 2 h after CCI (vehicle = 67 ± 7.6, INO-1001 = 95.8 ± 4.4 % uninjured hemisphere; n = 6/group, p = 0.03). In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI (n = 11/group, p ≤ 0.05). Histological damage did not differ between vehicle and INO-1001-treated mice after CCI. Treatment with INO-1001 prevented NAD+ depletion and improved outcome, although modestly, identifying PARP-mediated energy failure as a contributor to the pathological sequelae of TBI. Further study testing the effects of PARP inhibitors is warranted, specifically in models of brain injury where energy failure is seen.

AB - Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme best known for its role in DNA repair and as a mediator of NAD+ depletion and energy failure-induced cell death. We tested the effect of the potent and selective ideno-isoquinolone PARP-1 inhibitor INO-1001 after controlled cortical impact (CCI) in mice. Anesthetized adult male mice were subjected to moderate CCI (velocity 6 m/sec, depth 1.2 mm) or sham-injury. Immediately after CCI or sham-injury mice received either INO-1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 μl over 5 min) in a randomized fashion. At 2 h, contused brain tissue was dissected and NAD+ levels were measured. Separate mice underwent neuropathological outcome tests that included spatial memory acquisition (Morris water maze days 14-20), and assessment of contusion volume and hippocampal cell death at day 21. Local treatment with INO-1001 preserved brain NAD+ levels 2 h after CCI (vehicle = 67 ± 7.6, INO-1001 = 95.8 ± 4.4 % uninjured hemisphere; n = 6/group, p = 0.03). In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI (n = 11/group, p ≤ 0.05). Histological damage did not differ between vehicle and INO-1001-treated mice after CCI. Treatment with INO-1001 prevented NAD+ depletion and improved outcome, although modestly, identifying PARP-mediated energy failure as a contributor to the pathological sequelae of TBI. Further study testing the effects of PARP inhibitors is warranted, specifically in models of brain injury where energy failure is seen.

KW - Controlled cortical impact

KW - Head injury

KW - Ideno-isoquinolone

KW - Nicotinamide adenine dinucleotide

KW - Poly(ADP-ribose) synthetase

UR - http://www.scopus.com/inward/record.url?scp=34548320985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548320985&partnerID=8YFLogxK

U2 - 10.1089/neu.2007.0305

DO - 10.1089/neu.2007.0305

M3 - Article

C2 - 17711401

AN - SCOPUS:34548320985

VL - 24

SP - 1399

EP - 1405

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 8

ER -